Establishment of a prospective multicenter cohort for advanced non‐small cell lung cancer in China (CAPTRA‐Lung study)
Y Xu, L Zhang, J Fang, Z Wang, J Li, L Li, B Ai… - Thoracic …, 2018 - Wiley Online Library
The CAPTRA‐Lung study (NCT03334864) is a prospective observational study that will
capture real‐world data of patients with advanced or metastatic non‐small cell lung cancer …
capture real‐world data of patients with advanced or metastatic non‐small cell lung cancer …
Rate of hospitalization due to adverse event and length of stay for atezolizumab in second and third line metastatic non-small lung cancer (NSCLC) using phase 3 Oak …
Objectives The OAK study is a randomized phase III trial of atezolizumab vs. docetaxel in
prior treated NSCLC. The analysis population is the primary analysis population (425 …
prior treated NSCLC. The analysis population is the primary analysis population (425 …
Real-world progression-free survival as an endpoint in advanced non-small-cell lung cancer: replicating atezolizumab and docetaxel arms of the OAK Trial using data …
SK Mhatre, RJM Machado, TGN Ton, H Trinh… - medRxiv, 2022 - medrxiv.org
Background Evaluating cancer treatments in real-world data (RWD) requires informative
endpoints. Due to non-standardized data collection in RWD, it is unclear if and when …
endpoints. Due to non-standardized data collection in RWD, it is unclear if and when …
[HTML][HTML] Healthcare Resource Utilization and Associated Costs among Patients with Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy or …
J Ginés Rubió, O Delgado, A Callejo, M Domínguez… - Cancers, 2024 - mdpi.com
Simple Summary This observational, single-center, retrospective study aimed to describe
the real-world (RW) healthcare resource utilization (HCRU) among patients with advanced …
the real-world (RW) healthcare resource utilization (HCRU) among patients with advanced …
An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non–small-cell lung cancer
M Stewart, AD Norden, N Dreyer, HJ Henk… - JCO clinical cancer …, 2019 - ascopubs.org
PURPOSE This pilot study examined the ability to operationalize the collection of real-world
data to explore the potential use of real-world end points extracted from data from diverse …
data to explore the potential use of real-world end points extracted from data from diverse …
Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact® survey 2021
Aim: To report the treatment patterns of advanced/metastatic non-small-cell lung cancer
(NSCLC) in China from a physician survey (CancerMPact®). Materials & methods: A total of …
(NSCLC) in China from a physician survey (CancerMPact®). Materials & methods: A total of …
[HTML][HTML] Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012 …
A Wolf, JA Stratmann, S Shaid, N Niklas… - BMC Pulmonary …, 2023 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) have improved outcomes for
patients with advanced non-small cell lung cancer (NSCLC) versus chemotherapy in clinical …
patients with advanced non-small cell lung cancer (NSCLC) versus chemotherapy in clinical …
Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based …
IW Pan, R Mallick, R Dhanda, E Nadler - Lung Cancer, 2013 - Elsevier
Objectives This retrospective study used the US Oncology iKnowMed™ database, billing
claims, and chart reviews to report treatment patterns and outcomes in late-stage non-small …
claims, and chart reviews to report treatment patterns and outcomes in late-stage non-small …
Resource utilization among advanced squamous and non-squamous non-small cell lung cancer patients receiving second-line treatment in France, Germany, Italy …
CT Solem, JR Penrod, M Lees… - Value in …, 2015 - valueinhealthjournal.com
Objectives Across Europe, clinical and economic burden of advanced non-small cell lung
cancer (aNSCLC) remains high; regional variation and cost drivers are not completely …
cancer (aNSCLC) remains high; regional variation and cost drivers are not completely …
Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015–2018
M Veraldi, S Esposito, MD Naturale… - Journal of Oncology …, 2021 - journals.sagepub.com
Background Non-small-cell lung carcinoma (NSCLC) accounts for 85–90% of all forms of
lung cancer. Immuno-oncology represents a valid new approach but the high cost requires a …
lung cancer. Immuno-oncology represents a valid new approach but the high cost requires a …